文献速递前列腺癌

前列腺影像与诊断快速评估(RAPID)前列腺癌诊断路径

The rapid assessment for prostate imaging and diagnosis (RAPID) prostate cancer diagnostic pathway.
PubMed 文献 · BJU Int · 2022-11-10

RAPID路径是一项前瞻性注册研究,纳入三个中心2130例完成路径的患者,并与2435例前RAPID队列比较。路径使43%患者避免活检,临床显著癌检出率26%,Gleason 3+3检出率5.8%,诊断时间从32.1天降至15.9天。

要点

  • RAPID路径使43%(920/2130)患者避免活检,另有7.9%(168/2130)拒绝活检建议。
  • 临床显著癌(Gleason≥3+4)检出率26%(560/2130),Gleason 3+3检出率5.8%(124/2130)。
  • 诊断时间前RAPID队列32.1天(95%CI 29.3-34.9)vs RAPID组15.9天(95%CI 12.9-34.9)。

核心结论

  • RAPID前列腺癌诊断路径使43%男性避免活检,同时保持较好的临床显著癌检出和较低的 insignificant 癌检出,但存在中心间差异。

研究设计与样本

  • 前瞻性注册研究,纳入三个中心2017年4月3日至2020年3月31日完成RAPID路径的2130例患者,并与2435例前RAPID队列比较。

主要发现

  • 中位年龄66岁,中位PSA 6.6 ng/mL。
  • 43%(920/2130)患者避免活检,7.9%(168/2130)拒绝活检建议。
  • 各中心活检避免率分别为45%、36%、51%(P < 0.001)。
  • 30%(221/742)接受局麻(网格和步进器)经会阴活检。
  • 临床显著癌(任何Gleason评分≥3+4)检出率26%(560/2130),Gleason 3+3检出率5.8%(124/2130),后者在各中心间无显著差异(P = 0.7)。

关键数值与推荐

  • MRI评分4或5分以及PSA密度≥0.12且MRI评分3分的患者被建议进行活检。
  • 各中心活检避免率分别为45%、36%、51%(P < 0.001)。
  • 临床显著癌检出率26%(560/2130),Gleason 3+3检出率5.8%(124/2130)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 存在一些中心层面的差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To report outcomes within the Rapid Assessment for Prostate Imaging and Diagnosis (RAPID) diagnostic pathway, introduced to reduce patient and healthcare burdens and standardize delivery of pre-biopsy multiparametric magnetic resonance imaging (MRI) and transperineal biopsy. PATIENTS AND METHODS: A total of 2130 patients from three centres who completed the RAPID pathway (3 April 2017 to 31 March 2020) were consecutively entered as a prospective registry. These patients were also compared to a pre-RAPID cohort of 2435 patients. Patients on the RAPID pathway with an MRI score 4 or 5 and those with PSA density ≥0.12 and an MRI score 3 were advised to undergo a biopsy. Primary outcomes were rates of biopsy and cancer detection. Secondary outcomes included comparison of transperineal biopsy techniques, patient acceptability and changes in time to diagnosis before and after the introduction of RAPID. RESULTS: The median patient age and PSA level were 66 years and 6.6 ng/mL, respectively. Biopsy could be omitted in 43% of patients (920/2130). A further 7.9% of patients (168/2130) declined a recommendation for biopsy. The percentage of biopsies avoided among sites varied (45% vs 36% vs 51%; P < 0.001). In all, 30% (221/742) had a local anaesthetic (grid and stepper) transperineal biopsy. Clinically significant cancer detection (any Gleason score ≥3 + 4) was 26% (560/2130) and detection of Gleason score 3 + 3 alone constituted 5.8% (124/2130); detection of Gleason score 3 + 3 did not significantly vary among sites (P = 0.7). Among participants who received a transperineal targeted biopsy, there was no difference in cancer detection rates among local anaesthetic, sedation and general anaesthetic groups. In the 2435 patients from the pre-RAPID cohor, time to diagnosis was 32.1 days (95% confidence interval [CI] 29.3-34.9) compared to 15.9 days (95% CI 12.9-34.9) in the RAPID group. A total of 141 consecutive patient satisfaction surveys indicated a high satisfaction rate with the pathway; 50% indicated a preference for having all tests on a single day. CONCLUSIONS: The RAPID prostate cancer diagnostic pathway allows 43% of men to avoid a biopsy while preserving good detection of clinically significant cancers and low detection of insignificant cancers, although there were some centre-level variations.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Eldred-Evans D, Connor MJ, Bertoncelli Tanaka M, et al. The rapid assessment for prostate imaging and diagnosis (RAPID) prostate cancer diagnostic pathway. BJU Int. 2022. PMID: 36134435. doi:10.1111/bju.15899

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。